Posted by Michael Wonder on 06 Feb 2021
FDA authorises marketing of novel device to reduce snoring and mild obstructive sleep apnea in patients 18 years and older
5 February 2021 - Today, the U.S. FDA authorised marketing of a new prescription only device intended to reduce snoring and mild obstructive sleep apnea.
Unlike devices used while patients sleep, this is the first device used while awake that is intended to improve tongue muscle function, which in time can help prevent the tongue from collapsing backwards and obstructing the airway during sleep.
